Aduhelm

The Alzheimer’s Association and others have strongly criticized a decision by CMS to stand by its highly restrictive coverage for new dementia drugs.

An “atypical review process and corporate greed” factored into the FDA’s approval of Alzheimer’s drug Aduhelm in 2021, congressional investigators say. They recommend sticking to protocol...

Brain scans showed no adverse side effects in patients treated with Aduhelm for Alzheimer’s disease, a neurology clinic study has found.

The pharmaceutical firm Biogen has stopped a real-world clinical trial for its federally approved Alzheimer’s disease drug aducanumab (Aduhelm).

Coverage of aducanumab (Aduhelm) is officially limited to clinical trials only, the agency announced Thursday. Most stakeholders have called for restricted use while more efficacy and safety data is gathered,...

Patients weigh risks of taking new Alzheimer’s drug Aduhelm … Palliative care services vary by U.S. region for these groups … ​​The puzzling virus that affects almost everyone: Epstein-Barr …...

CDC reforming COVID-19 guidance … Nearly three-quarters of the U.S. now estimated to be immune to omicron variant … Brain synapse destruction culprit behind Alzheimer’s cognitive decline … Treatment...

The lawsuit alleges securities fraud on behalf of investors, adding to the ongoing fallout following Aduhelm’s controversial approval and Medicare’s questionable coverage proposal.

Higher pay not a cure-all for nurse retention, study shows … Majority of public support ongoing Aduhelm trials, would accept greater coverage costs, poll finds … 3G mobile network shutdown starts...

The Medicare coverage proposal for these drugs is too restrictive, limiting potential benefits to a select few, the two congressmen argue in a letter sent Monday to HHS Secretary Xavier Becerra.